Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study [version 1; peer review: 2 approved]

Maria N. Chitasombat, Siriorn P. Watcharananan

Division of Infectious disease, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand

Abstract

Background: Cytomegalovirus (CMV) is an important cause of infectious complications after kidney transplantation (KT), especially among patients receiving antithymocyte globulin (ATG). CMV infection can result in organ dysfunction and indirect effects such as graft rejection, graft failure, and opportunistic infections. Prevention of CMV reactivation includes pre-emptive or prophylactic approaches. Access to valganciclovir prophylaxis is limited by high cost. Our objective is to determine the burden and cost of treatment for CMV reactivation/disease among KT recipients who received ATG in Thailand since its first use in our center.

Methods: We conducted a single-center retrospective cohort study of KT patients who received ATG during 2010-2013. We reviewed patients' characteristics, type of CMV prophylaxis, incidence of CMV reactivation, and outcome (co-infections, graft function and death). We compared the treatment cost between patients with and without CMV reactivation.

Results: Thirty patients included in the study had CMV serostatus D+/R+. Twenty-nine patients received intravenous ganciclovir early after KT as inpatients. Only three received outpatient valganciclovir prophylaxis. Incidence of CMV reactivation was 43%, with a median onset of 91 (range 23-1007) days after KT. Three patients had CMV end-organ disease; enterocolitis or retinitis. Infectious complication rate among ATG-treated KT patients was up to 83%, with a trend toward a higher rate among those with CMV reactivation (P = 0.087). Patients with CMV reactivation/disease required longer duration of hospitalization (P = 0.018). The rate of graft loss was 17%. The survival rate was 97%. The cost of treatment among patients with CMV reactivation was significantly higher for both inpatient setting (P = 0.021) and total cost (P = 0.035) than in those without CMV.
Conclusions: Burden of infectious complications among ATG-treated KT patients was high. CMV reactivation is common and associated with longer duration of hospitalization and higher cost.

Keywords
antithymocyte globulin, cytomegalovirus, burden, kidney transplantation
Introduction
Human cytomegalovirus (CMV) is an important cause of infectious complications after kidney transplantation (KT). CMV infection can result in end-organ diseases and indirect effects such as opportunistic infections, graft rejection, and graft failure. Since the introduction of antithymocyte globulin (ATG) in transplantation, the incidence of CMV reactivation has increased up to 10–50%. To prevent CMV reactivation, prophylactic and preemptive approaches are almost equally effective. CMV prophylaxis reduces the incidence of CMV disease and associated mortality in solid organ transplant recipients. However, the cost of prophylaxis is high. Data from our center prior to ATG use showed that the incidence of symptomatic CMV reactivation among KT recipients (CMV D+/R+), was low (4.6%). In recent years, the use of ATG has been implemented nationwide.

In this study performed in Thailand, we evaluated the burden of symptomatic CMV reactivation/disease following the use of ATG in situations where CMV prophylaxis was not widely available and affordable. We also evaluated the outcome of ATG-treated patients in terms of infectious complications, graft loss, and cost of treatment in patients who developed CMV reactivation/disease and those who did not.

Methods
This was a retrospective cohort study of all ATG-treated (induction/antirejection therapy) KT patients aged ≥15 years at Ramathibodi Hospital, Bangkok, Thailand between January 2010 and July 2013. At our institution, routine oral antimicrobial prophylaxis included 1 year acyclovir (withheld during the period of anti-CMV exposure), 9 months isoniazid and 1 year cotrimoxazole. The strategy for CMV prophylaxis or preemptive therapy was based on the physician’s decision. Blood CMV viral load was monitored.

This study was approved by the Institutional Ethics Committee of Ramathibodi Hospital, Mahidol University (#12-56-24). For this retrospective study, formal informed consent was not required by the committee.

Data collection
We collected data from the records of patients on: demographic characteristics; underlying disease; type of KT; details of induction regimen and maintenance immunosuppression; serum creatinine; CMV serostatus of donors and recipients; CMV prophylaxis; clinical course; post-KT infectious complications; graft rejection; laboratory parameters at the time of CMV reactivation/disease (complete blood count, chemistry, liver function tests, immunosuppressive drug level, plasma CMV viral load) (COBAS Amplicor Monitor test; Roche Molecular Diagnostics); and treatment for CMV reactivation/disease. Outcomes including infectious complications, graft rejection, and death were measured at 3 and 6 months after KT until the end of the study in January 2014.

The cost of transplantation was analyzed among 26 KT patients (excluding four with missing data). We collected data for ganciclovir/valganciclovir use (duration and dosage) and medical expenses (overall cost of hospitalization and treatment, outpatient visits, emergency room visits, medication, laboratory tests, and imaging) from the initial hospital admission for KT until 6 months and at the end of study in January 2014. The direct cost of treatment for CMV infection/disease was not available because there was no system in the hospital to extract the specific data. We calculated the cost in US$ (2014 conversion rate of 32.506 THB to 1 US$) of prophylaxis with valganciclovir, with dose adjustment for glomerular filtration rate (GFR) for each patient according to serum creatinine at discharge.

Definition
Definition of CMV reactivation/disease was based on that of Ljungman et al. CMV reactivation was defined as new detection of CMV infection (plasma CMV viral load was used in this study) in patients who had previously had CMV serostatus positive (R+). CMV gastrointestinal disease was defined by combination of gastrointestinal symptoms, endoscopic mucosal lesions, and demonstration of CMV infection by histopathological examination, immunohistochemical analysis, or in situ hybridization of gastrointestinal tract biopsy specimens. CMV retinitis was diagnosed by an ophthalmologist from examination of typical lesions.

Statistics
Data were presented as median (range) and number (%). Categorical variables among patient groups were compared using the $\chi^2$ or Fisher’s exact test, and continuous variables were compared using the Mann–Whitney U test. Statistical analyses were performed by SPSS software version 17.0 (IBM SPSS Statistics, Chicago, Illinois, USA).

Results
A total of 30 KT patients received ATG during the study period. Patients’ characteristics are shown in Table 1. The majority of patients (n = 26; 87%) resided in rural areas. Six (20%) had a second KT, and 16 (53%) had living donor KT. ATG was used for induction therapy in 23 (77%) patients and antirejection therapy in seven. The total median ATG dose was 225 (105–700) mg. The maintenance regimen included mycophenolate mofetil, tacrolimus and prednisolone (n = 22, 73.3%); mycophenolate mofetil, cyclosporine and prednisolone (n = 4, 13.3%); cyclosporine, everolimus and prednisolone (n = 2, 6.6%); sirolimus, mycophenolate mofetil and prednisolone (n = 1, 3.3%); and everolimus, mycophenolate mofetil and prednisolone (n = 1, 3.3%). Delayed graft function occurred in 13 (43.3%) patients. Inpatient post-KT CMV prophylaxis with intravenous ganciclovir was given to 29 (96.6%) patients for a median duration of 13 (2-55) days. The median duration of hospitalization post-KT was 28 (16-78) days. Upon discharge, 16 (53%) patients had impaired graft function [GFR 40-59 ml/min in six (20%) patients, and 25-39 ml/min in five (17%) and 10-24 ml/min in five]. Two patients required hemodialysis at discharge because of early graft loss from severe antibody-mediated rejection. Outpatient CMV prophylaxis with valganciclovir was given to three (10%) patients. Rejection was diagnosed in 13 (43%) patients, but only 10 (76.9%) cases were confirmed by kidney biopsy. The median
Pseudomonas aeruginosa (3 (10%), 51 (25–68)). The cost of 100-day inpatient post KT to 200-day was US$2716 (range; US $210-6,336), and US $14,220, respectively. We calculated the median cost of valganciclovir prophylaxis according to GFR in each patient with normal GFR (900 mg/day) for 100 and 180 days was US$ 7,900 (1.37 (0.65–6.95) mg/dL). Infectious complications occurred in 25 (83%) patients (Table 2). Pneumocystis jirovecii pneumonia occurred in four patients who did not received cotrimoxazole at the time of diagnosis. Only one patient (ABO incompatibility) died at 266 days after KT because of several infectious complications (Pseudomonas aeruginosa septicemia, P. jirovecii pneumonia, invasive pulmonary aspergillosis, and disseminated Mycobacterium abscessus infection). Patient outcomes are shown in Table 1. ATG-treated KT patients with CMV reactivation/disease required longer duration of hospitalization after KT, with a median duration of 40 (21–78) days compared with patients without CMV reactivation of 26 (16–61) days (P = 0.018).

The median duration of follow-up was 542 (134–1583) days after KT. None of the patients who received valganciclovir prophylaxis developed CMV reactivation/disease. Thirteen patients developed CMV reactivation/disease. Six (46%) had low-grade CMV viremia without end-organ disease that spontaneously resolved after reduced immunosuppression. Four patients had CMV viremia plus fever, leukopenia and thrombocytopenia, which were compatible with CMV syndrome. Three patients had CMV end-organ disease: two with gastrointestinal disease and one with retinitis. The median onset of CMV reactivation/disease was 91 (23-1007) days after KT. Seven patients required anti-CMV therapy with a median duration of 25 (2-75) days, and intravenous ganciclovir for 12 (2-56) days. Laboratory parameters at the time of CMV reactivation/disease were: median white blood cell count 6,585 (3,082-9,962) cells/mm$^3$; 11 patients (85%) had lymphopenia, with a median absolute lymphocyte count of 519 (322-1,252) cells/mm$^3$; and median serum creatinine was 1.37 (0.65–6.95) mg/dL. Infectious complications occurred in 25 (83%) patients (Table 2). Pneumocystis jirovecii pneumonia occurred in four patients who did not received cotrimoxazole at the time of diagnosis. Only one patient (ABO incompatibility) died at 266 days after KT because of several infectious complications (Pseudomonas aeruginosa septicemia, P. jirovecii pneumonia, invasive pulmonary aspergillosis, and disseminated Mycobacterium abscessus infection). Patient outcomes are shown in Table 1. ATG-treated KT patients with CMV reactivation/disease required longer duration of hospitalization after KT, with a median duration of 40 (21–78) days compared with patients without CMV reactivation of 26 (16–61) days (P = 0.018).

The cost of KT was analyzed among 26 patients (excluding four with missing data) (Table 3). The cost of 100-day inpatient post KT, total inpatient post KT, and total post KT was significantly higher among patients with CMV reactivation/disease (P < 0.05). The cost of valganciclovir for patients with normal GFR (900 mg/day) for 100 and 180 days was US$ 7,900 and US$ 14,220, respectively. We calculated the median cost of valganciclovir prophylaxis according to GFR in each patient upon discharge of KT to 100-day and 200-day was US$2716 (range; US $210-6,336), and US $5,431 (range; US $420-12,673), respectively.

### Table 1. Patients’ baseline characteristics, treatment and outcome (n = 30).

| Parameters | N (%) |
|------------|-------|
| Age (median, range; years) | 51 (25–68) |
| Gender, male | 13 (43) |
| **Cause of end-stage renal disease** | |
| Idiopathic | 16 (53) |
| Glomerulonephritis | 9 (30) |
| Diabetic nephropathy | 3 (10) |
| Others† | 2 (7) |
| CMV D+/R+ | 30 (100) |
| **Immunologic risks** | |
| ABO incompatibility | 1 (3) |
| HLA mismatches >3 | 13 (43) |
| PRA >10% | 15 (50) |
| Cold ischemic time (median, range; minutes) | 39 (7–8640) |
| **Induction therapy (n = 29)** | |
| Anti-thymocyte globulin | 23 (77) |
| IL-2 antagonist | 5 (17) |
| Others† | 6 (21) |
| **Anti-rejection therapy (n=13)** | |
| Pulse methylprednisolone | 7 (54) |
| Anti-thymocyte globulin | 7 (54) |
| IVIG | 5 (38) |
| Plasmapheresis | 6 (46) |
| Adjustment of drug dosages/level‡ | 4 (30) |
| Combination of the regimen§ | 6 (46) |
| Cold ischemic time (median, range; minutes) | 39 (7–8640) |
| **Immunosuppressive agents** | (dose, mg/day) |
| Cyclosporine (n=5, 30%) | 150 (95–275) |
| Mycophenolate (n=27, 90%) | 1500 (1000–2000) |
| Tacrolimus (n=21, 70%) | 5 (1.5–9) |
| Prednisolone (n=29, 97%) | 20 (5–40) |
| Others† (n=2, 6%) | |
| Serum Cr at KT discharge (median, range; mg/dL) (n=28) | 1.56 (0.39–5.89) |
| **Outcome** | |
| Serum creatinine at follow-up (median, range; mg/dL) | 1.37 (0.65–6.95) |
| Duration of follow-up after KT (median, range; days) | 542 (134–1583) |
| Graft loss (n, %) | 5 (16) |
| Time to graft loss (median, range; days) | 266 (41–1038) |
| Death (n, %) | 1 (0.03) |

†Renal calculi and polycystic kidney disease; ‡ATG and IL-2 antagonist (n=1), IL-2 antagonist, rituximab and bortezomib (n=1); §sirolimus (n = 1, 3%; 1 mg/day), everolimus (n = 3, 10%; 3 (2–4) mg/day), pulse methylprednisolone and ATG (1, 8%), pulse methylprednisolone, ATG and plasmapheresis (1, 8%), ATG, IVIG and plasmapheresis (1, 8%). D+, Donor CMV seropositive; R+ recipient CMV seropositive; HLA, human leukocyte antigen; PRA, panel reactive antibody; IVIG, Intravenous immunoglobulin; Cr, creatinine; KT, kidney transplantation.

### Discussion

There is a lack of data about the burden of CMV reactivation/disease among KT recipients with CMV D+/R+ treated with ATG in Thailand. In Thailand, CMV prophylaxis is not widely available because of the high cost of valganciclovir. Pre-emptive
Table 2. Complications among ATG-treated KT recipients (n = 30).

| Characteristics                  | No CMV (n =17) | CMV (n=13) | P-value |
|-----------------------------------|----------------|------------|---------|
| Infectious complications (no, %) |                |            |         |
| Bacterial                         | 14 (82)        | 11 (85)    | 0.087   |
| Fungal‡                           | 3 (18)         | 4 (31)     | 0.666   |
| Non-CMV viruses †                 | 2 (12)         | 2 (15)     | >0.99   |
| Mycobacterium ‡                   | 1 (6)          | 2 (15)     | 0.565   |
| PJP                               | 3 (18)         | 1 (8)      | 0.613   |
| Rejection (no, %)                 |                |            |         |
| Timing of rejection (median; range, days) | 41 (2–266) | 13 (1–249) | 0.668  |
| Graft loss (no, %)                |                |            |         |
| Time to graft loss (median; range, days) | 332 (41–1038) | 2081 (208–2051) | 0.48  |

No CMV, patients with no evidence of CMV reactivation/diseases; CMV, patients with CMV reactivation/diseases. †Candida urinary tract infection (n = 3), candidemia (n = 2), invasive pulmonary aspergillosis (n =1), and disseminated histoplasmosis (n = 1). ‡BK-virus-associated nephropathy (n = 1), parvovirus-B19-associated pure red cell aplasia (n = 1), disseminated varicella zoster infection (n = 1), and rhinovirus lower respiratory tract infection (n = 1). ‡Disseminated Mycobacterium tuberculosis infection (n = 1), Mycobacterium hemophilum soft tissue infection (n = 1), disseminated Mycobacterium abscessus infection (n = 1) PJP, Pneumocystis jirovecii pneumonia

Table 3. Cost-outcome of ATG-treated KT recipients with/without CMV reactivation/diseases (n=26).

| Costs (in US$)       | All recipients (n=26) | CMV (n=12) | No CMV (n=14) | P-value |
|----------------------|-----------------------|------------|---------------|---------|
| 100-day post KT      |                       |            |               |         |
| Inpatient            | 18,667 (7,629–77,314) | 22,088 (13,731–77,314) | 15,565 (7,629–43,716) | 0.027   |
| Outpatient           | 3,928 (689–11,029)    | 3,671 (1,763–5,208)  | 4,637 (689–11,029)  | 0.382   |
| Sum                  | 21,390 (12,345–79,078)| 25,174 (17,389–79,078)| 19,871 (12,345–44,405)| 0.100   |
| 180-day post KT      |                       |            |               |         |
| Inpatient            | 19,923 (8,553–77,300) | 23,288 (14,613–77,300) | 17,460 (8,553–43,716) | 0.051   |
| Outpatient           | 7,432 (766–22,259)    | 7,213 (4,364–22,259)  | 7,783 (766–18,001)  | 0.837   |
| Sum                  | 25,530 (15,811–81,664)| 29,426 (21,479–81,664)| 24,159 (15,965–44,482) | 0.100   |
| Total post KT        |                       |            |               |         |
| Inpatient            | 21,071 (8,553–77,300) | 24,847 (14,612–77,300) | 18,796 (8,553–43,887) | 0.021   |
| Outpatient           | 16,894 (1,093–42,533) | 18,031 (4,364–42,533)  | 16,150 (1,093–32,253) | 0.681   |
| Sum                  | 39,791 (23,049–116,780)| 42,712 (25,737–116,780)| 34,641 (23,049–55,137) | 0.035   |

KT, kidney transplantation; P value calculated by Mann–Whitney U test.

treatment with plasma CMV viral load monitoring is difficult to achieve because of the need for frequent visits to the transplantation center. Our study is believed to be the first in Thailand to assess the burden of CMV reactivation after KT with ATG treatment. The incidence of CMV reactivation among CMV D+/R+ patients in our study was higher than in a previous study from our center prior to the use of ATG (53% vs.16.5 %)11. The incidence was similar to that in studies from Kuwait (43%) and Germany (53.8%)12,13. CMV reactivation is known to have immunomodulatory effects in transplant patients, resulting in allograft dysfunction and other infectious complications1. The overall rate of opportunistic infection is high in ATG-treated patients, and
there is a trend toward higher co-infection rates among patients with CMV reactivation/disease. The rate of graft rejection/loss was not increased among patients with CMV reactivation. However, the lack of statistical power that resulted from the small number of patients makes it impossible to draw firm conclusions.

Financial burden is a major problem in resource-limited settings. We performed a preliminary analysis of outcome in terms of cost, differentiating among patients with and without CMV reactivation/disease. We could not perform a full health economic analysis because of the small sample size. We demonstrated that the cost of KT was higher among patients with CMV reactivation/disease as a result of longer hospitalization, which was partly related to treatment of infectious complications. The cost within 100 days after KT was high (US$ 18,667) compared with that in a study from Chile (US $11,186). The possible reasons were the use of high-cost treatment including ATG, intravenous immunoglobulin, rituximab, and plasmapheresis in our study. A study from the US with similar patients showed that the cost was high, up to US$ 49,000 per admission. In a study from Australia, the cost at 12 months after KT was AU$ 89,188, 85,227, and 88,860 for no induction, induction with anti-interleukin-2, and induction with ATG, respectively. Most studies have focused on the cost of induction/rejection therapy; however, the cost after KT including treatment of infectious complications was not included.

One analysis has shown that universal CMV prophylaxis is cost-effective in KT patients with CMV R+. The lack of CMV prophylaxis could lead to even higher costs because of the cost of hospitalization among CMV D+/R– patients. A study from China revealed that the cost of KT was mainly related to drug treatment rather than hospitalization, which is different from the situation in western countries. In our study, the lack of universal valganciclovir prophylaxis in KT patients who received ATG induction was because of the high cost of medication. The alternative pre-emptive approach with monitoring CMV viral load for R+ patients has been described as an effective strategy. However, in our center an adequate pre-emptive approach was not possible because of the need for frequent follow-up visits, which were not feasible for most patients who resided in rural areas.

An economic model that simulated long-term costs and outcomes of prolonged prophylaxis with valganciclovir in a cohort of 10,000 D+/R– KT patients revealed that 200-days prophylaxis was more cost-effective than a 100-day regimen, with drug cost estimated based on normal GFR. In our study, most patients had impaired graft function (low GFR) as a result of the extended use of deceased donors. We calculated that the cost of valganciclovir prophylaxis according to low GFR at discharge up to 100-day was substantially less than the cost estimated with normal GFR. Our study demonstrated that the cost after KT among patients with CMV reactivation/disease was significantly higher than in those without CMV reactivation/disease.

The limitations of our study included a small sample size from a single-center retrospective study, and cost or sensitivity analysis of the cost-effectiveness was not intended. The heterogeneity of our patients was high, which limited the economic conclusions of this study. Another potential bias was the use of rituximab in few patients and the duration of follow-up time after KT. Generalization of our data should be done with caution, depending on the institutional protocol for KT. Future CMV prophylaxis or pre-emptive treatment in resource-limited settings should be evaluated in a prospective study with a larger sample size.

Conclusions
Our study highlighted the burden of CMV reactivation/disease and opportunistic infections in ATG-treated KT patients in a developing country where routine CMV prophylaxis may not be affordable.

Data availability
Dataset 1: Raw data for the study ‘Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study’, 10.5256/f1000research.16321.d219028

Grant information
The author(s) declared that there were no grants involved in supporting this work.

Acknowledgments
We thank Atiporn Ingsathit MD., PhD. for her suggestions of the statistical analysis. The data reported here were presented as a poster presentation at the IDWeek 2014, 8–12 October 2014, Philadelphia, USA. We thank Cathel Kerr, PhD, from Edanz Group for editing a draft of this manuscript.

References

1. De Keyzer K, Van Laecke S, Peeters P, et al.: Human cytomegalovirus and kidney transplantation: a clinician’s update, Am J Kidney Dis. 2011; 58(1): 118–26. Published Abstract | Publisher Full Text
2. Ljungman P, Griffths P, Paya C: Definitions of cytomegalovirus infection and disease in transplant recipients., Clin Infect Dis. 2002; 34(8): 1094–7. Published Abstract | Publisher Full Text
3. Lebranchu Y, Bridoux F, Büchler M, et al.: Immunophrophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy, Am J Transplant. 2002; 2(1): 48–56. Published Abstract | Publisher Full Text
4. Mourad G, Garrigue V, Squifflet JP, et al.: Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression.
5. Jamil B, Nicholls KM, Becker GJ, et al.: Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients. Transplantation. 2001; 72(6): 1050–9. PubMed Abstract | Publisher Full Text

6. Said T, Nampoory MR, Johny KV, et al.: Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies. Transplant Proc. 2004; 36(6): 1847–9. PubMed Abstract | Publisher Full Text

7. Huurman VA, Kalpoe JS, van de Linde P, et al.: Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care. 2006; 29(4): 842–7. PubMed Abstract | Publisher Full Text

8. Huurman VA, Kalpoe JS, van de Linde P, et al.: Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies. Transpl Infect Dis. 2004; 6(2): 63–8. PubMed Abstract | Publisher Full Text

9. Büchler M, Huraud de Ligny B, Madec C, et al.: Induction therapy by antithymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant. 2003; 17(6): 539–45. PubMed Abstract | Publisher Full Text

10. Hodson EM, Ladhani M, Webster AC, et al.: Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013; (2): CD003774. PubMed Abstract | Publisher Full Text

11. Watcharananan SP, Louhapanswat S, Chantratita W, et al.: Cytomegalovirus viremia after kidney transplantation in Thailand: predictors of symptomatic infection and outcome. Transplant Proc. 2012; 44(3): 701–5. PubMed Abstract | Publisher Full Text

12. Said T, Nampoory MR, Johny KV, et al.: Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies. Transplant Proc. 2004; 36(6): 1847–9. PubMed Abstract | Publisher Full Text

13. Witcz O, Hauser IA, Bartels M, et al.: Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Transplantation. 2012; 93(1): 61–8. PubMed Abstract | Publisher Full Text

14. Dominguez J, Harrison R, Alal R: Cost-benefit estimation of cadaveric kidney transplantation: the case of a developing country. Transplant Proc. 2011; 43(6): 2320–4. PubMed Abstract | Publisher Full Text

15. Tanriver B, Wright SE, Foster SV, et al.: High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc. 2008; 40(10): 3393–6. PubMed Abstract | Publisher Full Text

16. Morton RL, Howard K, Webster AC, et al.: The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrol Dial Transplant. 2009; 24(7): 2258–69. PubMed Abstract | Publisher Full Text

17. Luan FL, Kommareddi M, Ojo AO: Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients. Transplantation. 2011; 91(2): 237–44. PubMed Abstract | Publisher Full Text

18. Hellemans R, Beutels P, Ieven M, et al.: Cost analysis in favor of a combined approach for cytomegalovirus after kidney transplantation: a single-center experience. Transpl Infect Dis. 2013; 15(1): 70–8. PubMed Abstract | Publisher Full Text

19. Zhao W, Zhang L, Han S, et al.: Cost analysis of living donor kidney transplantation in China: a single-center experience. Ann Transplant. 2012; 17(2): 5–10. PubMed Abstract | Publisher Full Text

20. Blumberg EA, Hauser IA, Stanisic S, et al.: Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States. Transplantation. 2010; 90(12): 1420–6. PubMed Abstract | Publisher Full Text

21. Snyder RA, Moore DR, Moore DE: More donors or more delayed graft function? A cost-effectiveness analysis of DCD kidney transplantation. Clin Transplant. 2013; 27(2): 289–96. PubMed Abstract | Publisher Full Text

22. Chitasombat MN, Watcharananan SP: Dataset 1 in: Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study. F1000Research. 2018. http://www.doi.org/10.5256/f1000research.16321.d219028
Adisorn Lumpaopong
Department of Pediatrics, Phramongkutklao Hospital, Bangkok, Thailand

This study mentions about burden of CMV reactivation in KT patients who underwent transplantation. All patients had serology as D+/R+ and received ATG as induction. Since ATG is a highly immunosuppressive agent, the results of this study reveals CMV reactivation is common and other infectious complications also high. Medical expenses demonstrates different among CMV reactivation and without CMV group. As we know, cost of oral valganciclovir is expensive and need long period for prophylaxis. Preemptive treatment and frequent follow up might provide benefits in this patient group in Thailand that will provide cost saving for this situation.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Transplantation, tropical kidney disease

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 03 October 2018

https://doi.org/10.5256/f1000research.17829.r38840

© 2018 Jaijakul S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Siraya Jaijakul
Department of Medicine, Houston Methodist Hospital, Houston, TX, USA

In this manuscript Chitasombat and Watcharananan conducted a study of the burden and cost of treatment for CMV reactivation/disease among CMV serostatus D+/R+ kidney transplant (KT) recipients who received antithymocyte globulin (ATG) in a single-center in Thailand, which has limited healthcare resources. The study has showed that due to high cost of valganciclovir, patients were not able to afford the medication for using as universal CMV prophylaxis post KT. Consequently, since ATG could increase risk of developing CMV reactivation/disease in KT recipients, patients required longer hospitalization resulting in more financial burden.

The manuscript is well-written and well-organized. As mentioned by authors, generalization of the study is limited by a small sample size from a single-center setting. The result of 180-day inpatient cost post KT was not significant higher in CMV reactivation/disease group which could be due to a small sample size but we still could see the trend of higher financial burden among CMV reactivation/disease group.

A prospective study with a larger sample size or even in multi-center setting is warranted since this could impact treatment approaches for KT patients in Thailand. If CMV prophylaxis or preemptive treatment could be done, it would be interesting to see what would be an outcome and how much would it be for the cost of a serial CMV PCR monitoring and outpatient visits in the setting.

Is the work clearly and accurately presented and does it cite the current literature? Yes

Is the study design appropriate and is the work technically sound? Yes

Are sufficient details of methods and analysis provided to allow replication by others? Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com